Genomics Services
 
 
Tyrosine Kinase Sensitivity for KIT & PDGFRA
KIT and PDGFRA mutations are mutually exclusive in GISTs. Tyrosine Kinase Inhibitors(TKIs) are used treatment of GISTs. The frequency and type of mutations vary among these tumors, showing distinct clinical implications. Genetic testing is done for TKIs to check efficacy for drug and decide upon further treatment for better recovery of patient.

Sample Type

FFPE Tissue: Formalin Fixed Parafin Embedded (FFPE) tissue block with atleast 3-4 sections of tumor tissue. Tissue section should contain >70% tumor content verified by pathologist and should be sent along with 5 H&E stained and 5 unstained slides of tumor tissue.
 
Brochure           inquiry
 
 
EGFR (Epidermal Growth Factor Receptor)   |   ALK (Anaplastic lymphoma kinase)
BRAF (B-Raf proto-oncogene, serine/threonine kinase)   |   BRCA1 and BRCA2   |   CHECK2 (Check Point Homolog)
KRAS (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)   |   Tyrosine Kinase Sensitivity for KIT & PDGFRA
HER2 (Human Epidermal Growth factor Receptor 2) or ERBB2   |   TP53 (Tumor Protein p53)   |   BCR-ABL
Tamoxifen   |   NRAS Mutation   |   Tyrosine Kinase Sensitivity for Abl1 Mutations
HRAS Mutation (Harvey rat sarcoma viral Oncogene Homolog)   |   DPYD Mutation (for 5FU Sensitivity)
MAPK1 Mutation Analysis
 
 
Click Here to Zoom
 
Click Here to Zoom
 
Click Here to Zoom
 
Click Here to Zoom